It also evaluated putative targets of miR-495 involved in several pathways associated with AD pathophysiology, as well as the effects of MFB-ICSS treatment on hippocampal CA1 levels of its target, NRF2, and on corpus callosum thickness, both of which were significantly reduced in untreated STZ rats. The gene discussed is NFE2L2; the disease is Alzheimer disease.